Lantheus Holdings, Inc. is a leading radiopharmaceutical-focused company that develops, manufactures, and commercializes diagnostic and therapeutic products to assist clinicians in diagnosing and treating heart disease, cancer, and other conditions worldwide. Its portfolio includes DEFINITY, an injectable ultrasound enhancing agent for echocardiography; TechneLite, a technetium generator for nuclear medicine; Cardiolite for assessing heart muscle blood flow; PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent for prostate cancer lesions; Neurolite for stroke imaging; Xenon-133 for pulmonary function; and RELISTOR for opioid-induced constipation. The company also offers innovative AI-enabled solutions like PYLARIFY AI for quantitative PSMA PET/CT assessment, aPROMISE, Automated Bone Scan Index, and recent additions such as Flyrcado for heart blood flow evaluation, alongside expansions into Alzheimer's diagnostics through targeted radiodiagnostics. Lantheus Holdings, Inc. emphasizes precision medicine via strategic partnerships and biomarkers, serving oncology, cardiology, neurology, and non-oncologic sectors to enable clinicians to Find, Fight, and Follow disease. Founded in 1956 and headquartered in Billerica, Massachusetts, it plays a pivotal role in advancing radiopharmaceutical innovations.